Pharmacological interventions for psychosis in Parkinson's disease patients

Expert Opinion on Pharmacotherapy
Joseph H Friedman

Abstract

Psychosis is a common problem for people treated for Parkinson's disease. The syndrome is quite stereotypic, with hallucinations being the most common, followed by delusions. While the hallucinations are usually not very bothersome, the delusions are typically paranoid in nature. Treatment is often, but not always, required. This article reviews the therapeutic approaches of this syndrome focusing on drug treatments used once contributory factors have been removed. This includes a review of the evidence supporting the use of clozapine and, most recently, pimavanserin, the first drug with antipsychotic efficacy that has no effect on dopamine. Treatment with second generation antipsychotic drugs and cholinesterase inhibitors are also reviewed. Clozapine and pimavanserin have proven efficacy for Parkinson's disease psychosis (PDP), without impairing motor function. In clozapine's favor are its antipsychotic benefits seen within 1 week and its effectiveness in improving tremor in PD. However, this is counterbalanced by the need for blood monitoring, despite the extremely low doses used, and sedation. Pimanvanserin is well tolerated, without sedation or other significant side effects. Its onset of benefit, however takes 4-6 weeks. W...Continue Reading

References

Sep 1, 1989·Neurology·J H Friedman, M C Lannon
Jan 1, 1985·European Archives of Psychiatry and Neurological Sciences·E Scholz, J Dichgans
Sep 3, 1994·Lancet·B FordP Greene
Apr 1, 1994·Acta Neurologica Scandinavica·E N Jansen
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·R M TroschW C Koller
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezM Rosenfeld
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·J H Friedman, S A Factor
Aug 24, 2000·The Journal of Neuropsychiatry and Clinical Neurosciences·T EllisJ H Growdon
Dec 19, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·P J ReadingI G McKeith
May 1, 2002·Clinical Neuropharmacology·Joseph Bergman, Vladimir Lerner
Jul 12, 2002·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·G FabbriniG Meco
Sep 21, 2002·Biological Psychiatry·Alan BreierJoseph H Friedman
Oct 3, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·William G OndoJoseph Jankovic
Apr 20, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·P PollakI Bourdeix
Dec 14, 2004·The New England Journal of Medicine·Murat EmreRoger Lane
Apr 1, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·William G OndoGeorge Ringholz
Sep 9, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·David BurnRoger Lane
Oct 13, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Jose M RabeyColin Klein
Feb 3, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Bernard RavinaChristopher Goetz
Jan 6, 2009·Neurology·Robert A Gross, Karen C Johnston
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Paul ShotboltAnthony S David
Oct 20, 2009·Arquivos de neuro-psiquiatria·Arthur Kummer, Antonio Lucio Teixeira
Nov 13, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Herbert Y MeltzerJoseph H Friedman
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel Weintraub, David J Burn
Oct 6, 2011·Drugs & Aging·Clive BallardAnne Corbett
Mar 1, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph H Friedman
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
May 23, 2014·Expert Opinion on Pharmacotherapy·Leora L Borek, Joseph H Friedman
Sep 27, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Javier PagonabarragaJaime Kulisevsky
Jan 1, 2016·Parkinsonism & Related Disorders·A Komaragiri, J H Friedman
Sep 27, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Ronald B PostumaGünther Deuschl
Nov 23, 2016·Schizophrenia Bulletin·Flavie Waters, Charles Fernyhough
Jan 21, 2017·Nature Reviews. Neurology·Dominic H FfytcheDag Aarsland
Jun 18, 2017·Clinical Neuropharmacology·Joseph H Friedman
Jul 19, 2017·Journal of the Neurological Sciences·Shnehal PatelHubert H Fernandez
Aug 2, 2017·Parkinsonism & Related Disorders·Joseph H Friedman

❮ Previous
Next ❯

Citations

May 7, 2020·The Journal of Neuropsychiatry and Clinical Neurosciences·Alice PowellSimon J G Lewis
Dec 21, 2019·The Mental Health Clinician·James L Roerig
Jul 25, 2019·Neurología : publicación oficial de la Sociedad Española de Neurología·A Robles Bayón
Jun 2, 2020·Parkinsonism & Related Disorders·Kevin Kyle, Jeff M Bronstein
Nov 14, 2020·Expert Review of Neurotherapeutics·Alice PowellSimon J G Lewis
Oct 27, 2020·Advances in Clinical Neuroscience & Rehabilitation : ACNR·Rimona Weil, Suzanne Reeves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Expert Review of Clinical Pharmacology
Martin BroadstockAnne Corbett
Expert Opinion on Pharmacotherapy
Leora L Borek, J H Friedman
© 2022 Meta ULC. All rights reserved